Despite secondary prevention with oral anticoagulation (OAC), the risk for recurrent ischemic stroke (IS) and mortality is high in patients with atrial fibrillation (AF). However, OAC […]

MONTREAL — An open-label extension study of subcutaneous efgartigimod PH20 to treat chronic inflammatory demyelinating polyneuropathy (CIDP) showed durability of functional improvements to week 24, with […]

Good news for younger children suffering from the uncommon but debilitating gastrointestinal condition eosinophilic esophagitis (EoE). A randomized placebo-controlled study found the monoclonal antibody dupilumab (Dupixent) […]

MONTREAL — An investigational oral aldose reductase inhibitor, govorestat, significantly improved primary outcomes of physical function and serum sorbitol reduction in patients with sorbitol dehydrogenase (SORD) […]

ORLANDO, Florida — With glucagon peptide-1 receptor agonist (GLP-1 RA) drugs known to have a rapid rebound of weight gain upon discontinuation, women who stop using […]

BERLIN (Reuters) – Roche will end a lung cancer trial testing its new immunotherapy after the drug did not show a benefit over established treatment Keytruda […]

In 2018, Andrew Kraftson, MD, was approached by a colleague with a recurring dilemma: Primary care clinicians were both struggling with the complexities of obesity care, […]

Several large, practice-impacting trials in the multiple myeloma (MM) space were presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting in Chicago last […]

MONTREAL — A combination of intravenous immunoglobulin (IVIg) and methylprednisolone (MP) was associated with greater improvement in disability in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) […]